WealthPlan Investment Management LLC Purchases New Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

WealthPlan Investment Management LLC bought a new stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 339,292 shares of the company's stock, valued at approximately $4,530,000. WealthPlan Investment Management LLC owned about 0.50% of Perspective Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of CATX. Hills Bank & Trust Co acquired a new position in Perspective Therapeutics during the third quarter worth $13,722,000. Nicholson Wealth Management Group LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter worth about $21,390,000. WealthPLAN Partners LLC acquired a new stake in shares of Perspective Therapeutics during the 2nd quarter worth about $1,695,000. Bank of New York Mellon Corp lifted its holdings in Perspective Therapeutics by 214.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company's stock valued at $1,369,000 after purchasing an additional 93,548 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Perspective Therapeutics in the second quarter valued at about $841,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Trading Down 3.4 %

CATX traded down $0.38 during trading on Tuesday, reaching $10.71. 302,919 shares of the stock traded hands, compared to its average volume of 680,617. The company has a 50-day simple moving average of $13.00. Perspective Therapeutics, Inc. has a 12 month low of $2.20 and a 12 month high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. As a group, research analysts predict that Perspective Therapeutics, Inc. will post -0.87 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Truist Financial began coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective on the stock. Royal Bank of Canada decreased their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating on the stock in a report on Friday, August 16th. Wedbush reaffirmed an "outperform" rating and issued a $20.00 target price on shares of Perspective Therapeutics in a research note on Thursday, October 24th. UBS Group began coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They set a "buy" rating and a $20.00 price target on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, Perspective Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $20.63.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.